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Abstract
tRNase Z
L-utilizing efficacious gene silencing (TRUE gene silencing) is a newly developed technology to suppress
mammalian gene expression. TRUE gene silencing works on the basis of a unique enzymatic property of mammalian tRNase
Z
L, which is that it can recognize a pre-tRNA-like or micro-pre-tRNA-like complex formed between target RNA and artificial
small guide RNA (sgRNA) and can cleave any target RNA at any desired site. There are four types of sgRNA, 59-half-tRNA,
RNA heptamer, hook RNA, and ,14-nt linear RNA. Here we show that a 14-nt linear-type sgRNA against human miR-16 can
guide tRNase Z
L cleavage of miR-16 in vitro and can downregulate the miR-16 level in HEK293 cells. We also demonstrate
that the 14-nt sgRNA can be efficiently taken up without any transfection reagents by living cells and can exist stably in
there for at least 24 hours. The naked 14-nt sgRNA significantly reduced the miR-16 level in HEK293 and HL60 cells. Three
other naked 14-nt sgRNAs against miR-142-3p, miR-206, and miR-19a/b are also shown to downregulate the respective
miRNA levels in various mammalian cell lines. Our observations suggest that in general we can eliminate a specific cellular
miRNA at least by ,50% by using a naked 14-nt sgRNA on the basis of TRUE gene silencing.
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Introduction
tRNase Z
L i sal o n gf o r mo ft R N A3 9 processing endor-
ibonuclease (tRNase Z, or 39 tRNase) [1,2]. In human cells,
nuclear full-length tRNase Z
L works on precursor tRNAs to
process them by removing their 39 trailer, whereas cytosolic D30
tRNase Z
L appears to work on mRNAs to modulate gene
expressions by cleaving them under the direction of cellular
small noncoding RNAs such as 59-half-tRNA and miRNA [3,4].
It has been shown that cytosolic tRNase Z
L modulates the
PPM1F gene expression by cleaving its mRNA under the
direction of 59-half-tRNA
Glu [3] and that miR-103 can
downregulate gene expression through directing mRNA cleav-
age by cytosolic tRNase Z
L [4]. The cytosolic tRNase Z
L
together with the small noncoding RNAs appears to form a
broad gene regulatory network.
We have developed a technology for suppressing the expression
of a target gene by modulating this gene regulatory network under
the aegis of artificial small guide RNA (sgRNA) [5–9]. This
technology works on the basis of a unique enzymatic property of
mammalian tRNase Z
L, which is that it can recognize a pre-
tRNA-like or micro-pre-tRNA-like complex formed between
target RNA and artificial sgRNA and can cleave any target
RNA at any desired site [10–16]. There are four types of sgRNA,
59-half-tRNA [11], RNA heptamer [12], hook RNA [15], and
,14-nt linear RNA [16], and this technology is termed TRUE
gene silencing after tRNase Z
L-utilizing efficacious gene silencing.
The efficacy of TRUE gene silencing can become comparable to
that of the RNA interference [7] and can surpass it in some cases
[8].
miRNAs play important regulatory roles in many cellular
processes, and their dysfunction appears to cause many diseases
including cancer and heart disease [17]. It has been shown in
human cells that miR-15a and miR-16 work as tumor suppres-
sors, while miR-17-92, miR-19a/b, miR-21, and miR-181a/b
are oncogenic [18–20]. miR-122, which is abundant in liver cells,
has been shown to be a regulator of fatty-acid metabolism [21],
and its expression appears to be essential for replication of
hepatitis C virus [22]. Thus we can expect that elimination of
specific miRNAs in the cells would lead to cures of some diseases.
Indeed, downregulation of the miR-19 or miR-181 level in
myeloma cells by an antisense nucleic acid has been demonstrat-
ed to suppress tumor growth in nude mice [20]. And
oligonucleotides against miR-122 can reduce a blood cholesterol
level [21] and can also suppress the replication of hepatitis C
virus [22].
In this paper, we investigated if TRUE gene silencing can
eliminate specific miRNAs from human cells. And we show
that human tRNase Z
L can cleave miRNA under the direction
of 14-nt linear-type sgRNA in vitro and that naked 14-nt
sgRNA can significantly downregulate miRNA expression in
vivo.
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RNA/DNA Synthesis
The following eleven 59- and/or 39-phosphorylated RNAs with
full 29-O-methyl modifications, 39-Alexa-568-labeled 59-phosphor-
ylated sgR16(1–14) with full 29-O-methyl modifications, 39-FITC-
labeled 59-phosphorylated sgRNA14 with full 29-O-methyl mod-
ifications, and 59-FITC-labeled miR-16 were chemically synthe-
sized by Nippon Bioservice: sgR16(1–14), 59-pUUUACGUG-
CUGCUA(p)-39; sgR16(9–22), 59-pCGCCAAUAUUUACG-39;
sgR16(1–22), 59-pCGCCAAUAUUUACGUGCUGCUA(p)-39;
sgR16(1–12), 59-pUACGUGCUGCUA-39; sgR16(6–17), 59-
pAUAUUUACGUGC-39; sgR16(4–17), 59-pAUAUUUACGUG-
CUG-39; sgR16(4–15), 59-pAUUUACGUGCUG-39; sgR142(1–
14), 59-pUAGGAAACACUACAp-39; sgR142(1–23), 59-pUC-
CAUAAAGUAGGAAACACUACAp-39; sgR206(1–14), 59-pUU-
CCUUACAUUCCAp-39; sgR19(1–14), 59-pCAUGGAUUUG-
CACAp-39; sgRNA14, 59-pGGGGGCGGCCCCCG-39; miR-
16, 59-UAGCAGCACGUAAAUAUUGGCG-39.
The following DNA probes and primers were obtained from
Hokkaido System Science: miR-16 probe, 59-CGCCAATATT-
TACGTGCTGCTA-39; 5S rRNA probe, 59-AAGCCTACAG-
CACCCGGTATT-39; miR-16 reverse transcription primer, 59-
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG-
GATACGACCGCCAA -39; miR-16 forward primer, 59-CG-
CGCTAGCAGCACGTAAAT-39; miR-16 and miR-19a/b re-
verse primer, 59-GTGCAGGGTCCGAGGT-39; miR-19a/b
reverse transcription primer, 59-GTCGTATCCAGTGCAGGG-
TCCGAGGTATTCGCACTGGATACGACTCAGTT-39; miR-
19a/b forward primer, 59-CGCGCTGTGCAAATCTATGC-39;
5S rRNA forward primer, 59-GTCTACGGCCATACCACCC-
TG-39; 5S rRNA reverse primer, 59-AAGCCTACAGCACC-
CGGTATT-39; Bcl-2 mRNA forward primer, 59-GCCCTC-
ACTGGCCTCCTCCA-39; Bcl-2 mRNA reverse primer, 59-
GTGACAGGCCCAGCCACACC-39; b-actin mRNA forward
primer, 59-CTGGAACGGTGAAGGTGACA-39; b-actin mRNA
reverse primer, 59-AAGGGACTTCCTGTAACAACGCA-39.
The siRNA targeting the human tRNase Z
L mRNA was obtained
from Qiagen: sense, r(GACUCCGAGUCGAAUGAAA)d(TT);
antisense, r(UUUCAUUCGACUCGGAGUC)d(TG). Silencer
Negative Control No. 1 siRNA (#4611; Ambion) was used as a
scramble siRNA.
In vitro RNA Cleavage Assay
In vitro RNA cleavage assays for the FITC-labeled miR-16
(2 pmol) were carried out at 37uC in the presence of the unlabeled
sgRNAs (20 pmol) using histidine-tagged human D30 tRNase Z
L
(50 ng) in a mixture (6 ml) containing 10 mM Tris-HCl (pH 7.5),
and 3.3 mM MgCl2. After resolution of the reaction products on a
15% polyacrylamide-8 M urea gel, the gel was analyzed with a
Typhoon 9210 (GE Healthcare).
Cell Culture and Transfection
Various mammalian cells, HEK293 [23], HeLa [24], Jurkat
[25], HL60 [26], DAUDI (obtained from RIKEN BioResource
Center, Tsukuba, Japan), C2C12 [27], and RPMI-8226 [28], were
cultured in RPMI-1640 or DME media (Wako) supplemented
with 10% fetal bovine serum (FBS; MP Biomedicals) and 1%
penicillin-streptomycin (Invitrogen) at 37uCi n5 %C O 2 humid-
ified incubator.
HEK293 cells were transfected with sgRNA or with sgRNA and
scramble or anti-tRNase-Z
L siRNA using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol, and
cultured for further 42 hours.
Northern Analysis
Total RNA was extracted with ISOGEN. The RNA samples
(10 mg) were separated by 15% polyacrylamide/8 M urea gel
electrophoresis, and electrically transferred to a Hybond N
+
membrane (GE Healthcare). The membrane was ultraviolet-
crosslinked, probed with a 59-
32P-labeled deoxyoligonucleotide in
a QuickHyb buffer (Stratagene) at 45uC, and analyzed with the
Typhoon 9210.
Real-Time PCR
Total RNA was extracted from cells using ISOGEN. The
cellular amounts of miR-16, miR-142-3p, and miR-206 were
quantitated by a StepOne Real Time PCR System using TaqMan
MicroRNA Assays and TaqMan MicroRNA Reverse Transcrip-
tion Kit (Applied Biosystems). The miR-16, miR-19a/b, Bcl-2
mRNA and b-actin mRNA levels were quantitated by real-time
PCR using a LightCycler 480 SYBR Green I Kit (Roche).
Western Analysis
Whole cell extracts dissolved in a buffer (50 mM Tris-HCl
pH 6.8, 2% SDS, 10% glycerol, 100 mM dithiothreitol) were
separated by SDS/7.5% polyacrylamide gel electrophoresis, and
transferred to a nitrocellulose membrane. The membrane was
probed with polyclonal antibodies raised to a human tRNase Z
L
peptide (amino acid 812–826) or a monoclonal antibody against
human b-actin (Sigma) using the ECL Western Blotting Detection
System (GE Healthcare).
Fluorescent Microscopic Analysis
HL60 and RPMI-8226 cells (5610
4 cells/well) were cultured in
24-well plates in the absence and presence of 1 mM Alexa-568-
labeled sgR16(1–14), and HEK293 cells (5610
4 cells) were
likewise in a fibronectin-coated chamber slide. After 24 hours,
the cells were rinsed twice with 16phosphate-buffered saline (PBS)
and fixed with 4% paraformaldehyde in 16PBS for 3 min.
Hoechst 33342 (DOJINDO) was used to stain DNA, and the cells
were analyzed with the fluorescent microscope system Axio
Imager.M2 (Zeiss).
sgRNA Survivability Test
Human cells (0.8–1610
5 cells/well) were cultured in a 24-well
plate, and 24 hours after the addition of 1 mM of the 39-Alexa-568-
labeled sgR16(1–14) or the 39-FITC-labeled sgRNA14 to the
medium, the cells were harvested and washed four times with 1 ml
of 16PBS. Total RNA was extracted from the cells with ISOGEN,
and separated on a 20% polyacrylamide-8 M urea gel. The gel
was analyzed with the Typhoon 9210.
Statistical Analysis
Differences between control and experimental groups were
evaluated by the Student’s t-test.
Results and Discussion
tRNase Z
L can Cleave miR-16 under the Direction of a 14-
nt sgRNA
To examine if tRNase Z
L can cleave miRNA under the
direction of sgRNA, we performed an in vitro tRNase Z
L cleavage
assay for human miR-16. A 14-nt linear-type sgRNA, sgR16(1–
14), which is complementary to the 1st–14th nucleotides of miR-
16, and a control 14-nt RNA, sgR16(9–22), which is complemen-
tary to 9th–22nd nucleotides of miR-16, were chemically
synthesized as 29-O-methyl RNA (Figure 1A). As expected, miR-
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L under the direction
of sgR16(1–14), but not sgR16(9–22) (Figure 1B).
We also tested 4 more linear-type sgRNAs against miR-16 for
their guiding ability. These sgRNAs, sgR16(1–12), sgR16(6–17),
sgR16(4–17), and sgR16(4–15), are designed to be complementary
to 12 or 14 nucleotides of miR-16 (Figure 1E,F). All these sgRNAs
guided tRNase Z
L cleavage of miR-16, albeit inefficiently
compared with sgR16(1–14). The cleavages directed by
sgR16(6–17), sgR16(4–17), and sgR16(4–15) occurred primarily
after a nucleotide corresponding to the discriminator nucleotide,
whereas those by sgR16(1–14) and sgR16(1–12) occurred primar-
ily 1-nt downstream and 1-nt upstream, respectively. These
cleavage site fluctuations have been previously described as a
property of tRNase Z
L [16,29].
These results suggest that both the length and the binding site of
sgRNA are important for its efficient guiding ability. We focused
on 14-nt sgRNAs that are complementary to the 1st–14th
nucleotides of miRNAs for the following in vivo analyses.
Downregulation of the miR-16 level by TRUE Gene
Silencing
Next, we examined if sgR16(1–14) works as sgRNA against
miR-16 in human cells. sgR16(1–14), sgR16(9–22), or the 22-nt
antisense RNA sgR16(1–22) was transfected into HEK293 cells,
and the cellular miR-16 level was analyzed by northern blotting
and real-time PCR. sgR16(1–14) and sgR16(1–22) significantly
downregulated the miR-16 level, whereas sgR16(9–22) did not at
all (Figure 1C,D). We also carried out co-transfection experiments
with siRNA against human tRNase Z
L mRNA. The reduction in
the miR-16 level by sgR16(1–14) was restored by downregulating
the tRNase Z
L expression, while the reduction by sgR16(1–22) was
not affected (Figure 1C,D).
Figure 1. Downregulation of the miR-16 expression by TRUE gene silencing. (A and E) Structures of the complexes of sgRNAs with human
miR-16. An arrow indicates the tRNase Z
L cleavage site. (B and F) In vitro tRNase Z
L cleavage assays. 59-fluorescein-labeled miR-16 was incubated with
recombinant human D30 tRNase Z
L in the absence or presence of sgRNA, which was phosphorylated at the 59 end but not at the 39 end. The
cleavage products were analyzed on a denaturing 15% polyacrylamide gel. L, alkaline ladder of miR-16; I, input RNA. (C) Northern analysis for human
miR-16. Total RNA was extracted from the HEK293 cells that were transfected with mock, 100 nM of sgR16(1–14), sgR16(9–23) or sgR16(1–23) without
(left) or together with 100 nM of the anti-tRNase-Z
L siRNA (right). sgR16(1–14), sgR16(9–23), and sgR16(1–23) were phosphorylated at the 59 end but
not at the 39 end. The total RNA (10 mg) was separated on a denaturing 15% polyacrylamide gel. Bromophenol blue (,10 nt) and xylene cyanol
(,35 nt) were used as size markers. (D) The same RNA samples as in C were analyzed by a StepOne Real Time PCR System. The miRNA levels are
normalized against the RNU48 levels. Error bars indicate s.d. (n=3). *, P,0.005.
doi:10.1371/journal.pone.0038496.g001
Figure 2. tRNase Z
L is responsible at least partly for the reduction in the miR-16 level by sgR16(1–14). (A) Quantitation of the miR-16
level in HEK293 cells with a LightCycler 480 SYBR Green I Kit. The HEK293 cells were transfected with mock, 35 nM of sgR16(1–14) or sgR16(1–22)
together with 50 nM of the scramble siRNA or the anti-tRNase-Z
L siRNA. sgR16(1–14) and sgR16(1–22) were phosphorylated at both 59 and 39 ends.
The miR-16 levels are normalized against the 5S rRNA levels. Error bars indicate s.d. (n=3). *, P,0.001. (B) Western blot analysis. The tRNase Z
L level
under the above transfection conditions was analyzed. b-actin was used as a loading control.
doi:10.1371/journal.pone.0038496.g002
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conditions, in which 59- and 39-phosphorylated sgR16(1–14) and
sgR16(1–22) were used, and also analyzed tRNase Z
L levels by
western blotting. In one set of the experiments, we obtained results
similar to the above ones, but restoration of the miR-16 level
reduction by downregulating the tRNase Z
L expression was
incomplete (Figure S1A). This may be due to incomplete
elimination of tRNase Z
L (Figure S1B) and/or due to a possible
weak binding and sequestering effect of sgR16(1–14).
In another set of the experiments, in which a scramble siRNA
was used as a control, we also obtained similar results (Figure 2).
Together, these results suggest that tRNase Z
L is responsible at
least partly for the reduction by sgR16(1–14) but not by sgR16(1–
22) and that TRUE gene silencing can downregulate the miRNA
expression. The mechanism by which sgR16(1–22) acts on the
miR-16 level would be through binding and sequestering [20–22].
Naked Linear-type sgRNA can be Taken up by Living Cells
We investigated how efficiently linear-type sgRNA can be taken
up by living cells without any transfection reagents and can
downregulate the miRNA expression. HL60 cells were cultured in
the presence of 1 mM of the naked 14-nt 39-Alexa-568-labeled
sgR16(1–14) and analyzed with a fluorescent microscope. This
sgRNA was indeed efficiently taken up without any transfection
reagents by HL60 cells (Figure 3A). RPMI-8226 and HEK293
cells also took up the naked sgRNA efficiently (Figure 3A). We also
showed that another 14-nt RNA, sgRNA14, can be taken up
nakedly by HeLa, HEK293, and Jurkat cells (Figure S2A,B and
Text S1).
Furthermore, we demonstrated by polyacrylamide gel analysis
of total RNA from HL60, RPMI-8226, and HEK293 cells that at
least a part of the taken-up sgR16(1–14) molecules exist stably for
at least 24 hours in the cells (Figure 3B,C). And at least a part of
sgRNA14 molecules were also stable for at least 24 hours in HeLa,
HEK293, and Jurkat cells (Figure S2C). However, the amount of
sgR16(1–14) recovered from HEK293 cells that took it up with the
aid of a transfection reagent was much higher than that recovered
from the cells that took it up nakedly (Figure 3C), suggesting that
sgR16(1–14) can be taken up more easily and/or can exist more
stably in the presence of the transfection reagent.
Reduction in the miR-16 Level by a Naked 14-nt sgRNA
We cultured HEK293 cells in the presence of 1 mM of naked
sgR16(1–14), sgR16(9–22), or sgR16(1–22), and analyzed the
cellular miR-16 level by real-time PCR. These RNAs were
phosphorylated at the 59 end but not at the 39 end. While
sgR16(9–22) and sgR16(1–22) did not reduce the miR-16 level at
all, sgR16(1–14) significantly reduced the level to 58% (Figure 4A).
Figure 3. Naked linear-type sgRNA can be taken up by living cells. (A) Microscopic images of HL60, RPMI-8226 and HEK293 cells. The cells
were fixed and stained with Hoechst 3342, 24 hours after the cells were cultured in the absence or presence of 1 mM of the naked 39-Alexa-568-
labeled sgR16(1–14). (B and C) sgRNA survivability tests. The 39-Alexa-568-labeled sgR16(1–14) was analyzed on a denaturing 20% polyacrylamide gel.
The sgRNA recovered from inside the cells are shown, which took it up nakedly or with the aid of Lipofectamine 2000 (LF). The band denoted by an
asterisk would correspond to a degradation product of sgR16(1–14). Standard, 39-Alexa-568-labeled sgR16(1–14).
doi:10.1371/journal.pone.0038496.g003
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reagent, in which sgR16(1–22) almost completely eliminated
cellular miR-16 (Figure 1D).
Wealso carried out a similar experiment with HL60cells using59-
and 39-phosphorylated sgR16(1–14) and sgR16(1–22). Likewise
sgR16(1–14) significantly reduced the miR-16 level to 53%, but in
contrastsgR16(1–22)alsodid workalmostperfectly(Figure 4B).This
was also the case in HEK293 cells (data not shown). This
discrepancy would be attributed to the phosphorylation at the 39
end, which appears to make RNA more efficient in being taken up
byhumancellsand/ormorestableinthecellsthanRNAwithno 39-
phosphate judging from a result of the RNA survivability test (data
not shown).
Furthermore, to show that the knockdown of miR-16 is
functional, we examined its endogenous target, the Bcl-2 mRNA,
for the stability [30]. The Bcl-2 mRNA levels in HL60 cells were
upregulated to 122% and 137% by downregulating the miR-16
levels by sgR16(1–14) and sgR16(1–22), respectively (Figure 4B,C).
This result implies that sgR16(1–14) can stabilize the Bcl-2 mRNA
by reducing the miR-16 level and subsequently inhibiting the
mRNA transport to P-bodies.
Downregulation of miRNA Expression Levels by Naked
14-nt sgRNAs
We also examined three naked 14-nt sgRNAs against miR-142-
3p, miR-206, and miR-19a/b for their guiding ability. sgR142(1–
14) significantly reduced the miR-142-3p level to 48% and 47% in
HL60 and DAUDI cells, respectively, without any transfection
reagents, whereas sgR142(1–23) decreased the level slightly in both
cell lines (Figure 5A). The 22-nt 59-a n d3 9-phosphorylated
sgR16(1–22) worked very efficiently even in a naked form
(Figure 4B), whereas the 23-nt sgR142(1–23), which was also 59-
and 39-phosphorylated, barely worked, suggesting that, unlike 14-nt
sgRNAs, the efficiency of naked 22–23-nt RNAs in being taken up
by living cells and/or their stability in the cells may change
depending on their sequence itself as well as 39-phosphorylation
status.
The miR-206 expression in C2C12 cells was efficiently down-
regulated to 22% by sgR206(1–14), and the miR-19a/b level in
RPMI-8226cellswasreducedto28%bysgR19(1–14)(Figure5B,C).
These observations imply that in general we can eliminate a specific
cellular miRNA at least by ,50% by using 1 mM of a naked 14-nt
sgRNA on the basis of TRUE gene silencing.
Figure 4. Reduction in the miR-16 level by a naked 14-nt sgRNA. (A) Quantitation of the miR-16 level in HEK293 cells with a StepOne Real
Time PCR System. Total RNA was extracted from the HEK293 cells that were cultured for 24 hours in the absence or presence of sgR16(1–14),
sgR16(9–22), or sgR16(1–22), which was phosphorylated at the 59 end but not at the 39 end. The miR-16 levels are normalized against the RNU48
levels. Error bars indicate s.d. (n=3). *, P,0.05. (B) Quantitation of the miR-16 level in HL60 cells with a LightCycler 480 SYBR Green I Kit. Total RNA
was extracted from the HL60 cells that were cultured for 24 hours in the absence or presence of sgR16(1–14) or sgR16(1–22). sgR16(1–14) and
sgR16(1–22) were phosphorylated at both 59 and 39 ends. The miR-16 levels are normalized against the 5S rRNA levels. Error bars indicate s.d. (n=3).
*, P,0.001. (C) Real-time PCR analysis for the Bcl-2 mRNA level in HL60 cells. Total RNA was extracted from the HL60 cells that were cultured for 24
hours in the absence or presence of sgR16(1–14) or sgR16(1–22). sgR16(1–14) and sgR16(1–22) were phosphorylated at both 59 and 39 ends. The Bcl-2
mRNA levels are normalized against the b-actin mRNA levels. Error bars indicate s.d. (n=3). *, P,0.001.
doi:10.1371/journal.pone.0038496.g004
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Our results suggest that TRUE gene silencing can be used for
RNA therapy targeting disease-causing miRNA. miRNAs to be
targeted would include miR-19a/b and miR-21 for cancer therapy
and miR-122 for hypercholesterolemia and hepatitis C treatments.
As 14-nt sgRNA can be taken up easily by the cells without any
carrier reagents such as cholesterol and cationic liposome, and can
guide tRNase Z
L to cleave miRNA, TRUE gene silencing may be
advantageous over a technology based on the inhibitory mecha-
nism through binding and sequestering [20–22].
Supporting Information
Figure S1 The reduction in the miR-16 level by sgR16(1–
14) is attributable at least partly to tRNase Z
L. (A)
Quantitation of the miR-16 level in HEK293 cells with a
LightCycler 480 SYBR Green I Kit. The HEK293 cells were
transfected with mock, 35 nM of sgR16(1–14) or sgR16(1–22)
together with mock or the anti-tRNase-Z
L siRNA. sgR16(1–14)
and sgR16(1–22) were phosphorylated at both 59 and 39 ends. The
miR-16 levels are normalized against the 5S rRNA levels. Error
bars indicate s.d. (n=3). *, P,0.001. (B) Western blot analysis.
The tRNase Z
L level under the above transfection conditions was
analyzed. b-actin was used as a loading control.
(PDF)
Figure S2 Naked 14-nt sgRNA can be taken up by living
cells. (A) Confocal laser microscopic images of HeLa cells. HeLa
cells were fixed and stained with ethidium bromide 24 hours after
the cells were cultured in the absence or presence of 1 mM of the
naked 14-nt 39-FITC-labeled sgRNA14. (B) Fluorescence ratio-
metric analysis. Fluorescence ratiometric images of HeLa,
HEK293, and Jurkat cells were taken 24 hours after the cells
were cultured in media containing 1 mM of the 39-FITC-labeled
sgRNA14. (C) sgRNA survivability tests. The 39-FITC-labeled
sgRNA14 was analyzed on a denaturing 20% polyacrylamide gel.
The standard 39-FITC-labeled sgRNA14 (S) and the sgRNA14
retrieved from inside the cells (R) are shown. Asterisks denote the
recovered sgRNA. The bands shifted upward would correspond to
complexes between the sgRNA and small cellular RNAs.
(PDF)
Text S1 Supplementary Materials and Methods.
(PDF)
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